Mad Money

Cramer Remix: The most dangerous stock group

Cramer Remix: This stock group is dangerous!

Every day, Jim Cramer hears that oil is about to roll over, but now it seems things have finally turned around.

While many may not want to accept that the global landscape is improving, Cramer sees signs that things are bouncing back faster than anticipated, especially for oil.

"I think the clock is ticking, and the deals are about to happen," the "Mad Money" host said.

And when oil stocks roar, Cramer also expects banks, agriculture, commodity chemical stocks to accelerate as well.

On the flipside, the usual stocks that investors flee to for safety have done poorly. This would account for the decline in Coca-Cola, as investors search for stocks that benefit when the global economy is recovering.

That means the most dangerous stocks in this environment are utilities, Cramer said. Utilities tend to perform poorly when interest rates go higher from natural demand and there is no flight to safety.

Read More Cramer: Oil deals are about to happen

A red star fronts a pressure tank at the Yanlian Oil Refinery in Yan'an, 25 May 2005, north of Xian in western China's Shaanxi province.

The highly public leadership dispute for PulteGroup just took another contentious turn. The company's founder, William Pulte, has called for James Postl to immediately resign from the board of directors.

This comes just weeks after his request for current CEO Richard Dugas to resign.

In a letter released by William Pulte on Wednesday, he wrote "It is my conviction that Richard Dugas and James Postl must resign immediately from all their positions with the company."

Additionally, Pulte stated that in the event that Dugas and Postl refuse to resign immediately and be replaced by direct shareholder representatives, he will vote against the entire board in this year's shareholder meeting.

In an interview with CNBC's Jim Cramer on Wednesday, Pulte's grandson and Pulte Capital Partners CEO Bill Pulte said "We believe that Jim and Richard are still really running the company, remember they hold chairman, CEO and lead director."

Read More Pulte feud aims at board, calls for resignation

Cramer has a hunch that Intel could be on the verge of splitting itself into two.

He believes that the world's No. 1 chipmaker could break itself into a P.C. semiconductor company, and a high growth company geared towards the internet of things and data centers.

Cramer came to this conclusion when Intel announced that CFO Stacy Smith would move to a new position to oversee sales and manufacturing.

When Cramer interviewed Intel CEO Bryan Krzanich on CNBC's "Squawk on the Street" on Wednesday, he posed the question to him if the company could break up and have Stacy run the slower growth P.C. chip business, and Krzanich run the faster growing segment.

"Bryan made me feel like I read his mind. And why not? I think the move would unlock tremendous value," he said.

Read More Cramer: Intel could split in two

PulteGroup Inc. signage directs visitors to the Sage housing development sales center in San Jose, California.
David Paul Morris | Bloomberg | Getty Images

Last week, JPMorgan kicked off banking earnings with a quarter that was better than what many feared, and the entire group jumped on the news.

Since then, all of the major financials have also reported: Goldman Sachs, Bank of America, Wells Fargo, Citigroup and Morgan Stanley.

"Any way you slice it, this was a rough quarter for the banks, but none of them denied it. They did not apologize and they did not make excuses," Cramer said.

Ultimately, Cramer expects the banking cohort to head higher, especially now that investment banking divisions seem to be improving. The group has been scorned for years, and now it is their time to shine.

After a hideous sell-off in biotech this year, the group has started to finally rebound. One of those stocks is BioMarin, one of the leading makers of orphan drugs that treat rare diseases.

BioMarin has multiple drugs on the market, including three for rare metabolic disorders, one for phenylketonuria and a recently approved drug for duchenne muscular dystrophy. Additionally, it just released strong data on a hemophilia drug and a treatment for a common form of dwarfism.

Cramer spoke with BioMarin's CEO Jean-Jacques Bienaimé, who confirmed the encouraging results found in its early-stage hemophilia therapy.

"The results are definitely above our expectations, and above most key experts in the field expectations," Bienaimé said

In the Lightning Round, Cramer gave his take on a few caller-favorite stocks:

KKR & Co: "We need a better IPO market so they can bring public some of the stocks that they have, and I think we are going to get it. So, therefore I think buy."

Fiesta Restaurant: "They seem to have lost a little bit of momentum. The stock is a little bit high in price. Let's listen to what Yum has to say tomorrow. You know I think that one is good, I said buy a little before and maybe buy some after."

Read MoreCramer: The stock to buy when IPOs heat up